|
gptkbp:instanceOf
|
gptkb:drug
gptkb:monoclonal_antibody
|
|
gptkbp:administeredBy
|
intravenous infusion
|
|
gptkbp:approvalYear
|
1998
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
L04AB02
|
|
gptkbp:biosimilar
|
gptkb:Avsola
gptkb:Inflectra
gptkb:Ixifi
gptkb:Renflexis
|
|
gptkbp:brand
|
gptkb:Remicade
|
|
gptkbp:CASNumber
|
gptkb:170277-31-3
|
|
gptkbp:composition
|
chimeric IgG1 monoclonal antibody
|
|
gptkbp:contraindication
|
severe infections
active tuberculosis
|
|
gptkbp:developedBy
|
gptkb:Merck_&_Co.
gptkb:Janssen_Biotech
|
|
gptkbp:firstApprovedCountry
|
gptkb:United_States
|
|
gptkbp:halfLife
|
8-10 days
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
infliximab
|
|
gptkbp:immunogenicity
|
can induce anti-drug antibodies
|
|
gptkbp:interactsWith
|
live vaccines
other immunosuppressants
|
|
gptkbp:KEGGID
|
D08123
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
TNF-alpha inhibitor
|
|
gptkbp:molecularWeight
|
149100 Da
|
|
gptkbp:patentExpired
|
yes
|
|
gptkbp:pregnancyCategory
|
B (US)
|
|
gptkbp:prescribes
|
moderate to severe autoimmune diseases
|
|
gptkbp:PubChem_CID
|
gptkb:DB00065
CHEMBL1201587
|
|
gptkbp:riskFactor
|
reactivation of hepatitis B
increased risk of malignancy
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
headache
infections
rash
infusion reactions
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:target
|
gptkb:tumor_necrosis_factor_alpha
|
|
gptkbp:UNII
|
GSK39JAR4B
|
|
gptkbp:usedFor
|
gptkb:Crohn's_disease
gptkb:psoriatic_arthritis
ulcerative colitis
rheumatoid arthritis
ankylosing spondylitis
plaque psoriasis
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:Remicade
|
|
gptkbp:bfsLayer
|
5
|